Antigenics Receives Patent for Heat Shock Protein-Based Cancer Treatment

Strategic Insights -

Antigenics, L.L.C. announced that the U.S. Patent and Trademark Office (PTO) has issued Patent No. 5,750,119, covering the company's proprietary heat shock protein (HSP) technology for cancer treatment. This patent represents a significant milestone for Antigenics, as it is the only U.S.-issued patent for the use of HSPs in cancer treatment. The company's approach involves using HSP-antigen complexes derived from individual patient tumors or non-autologous tissue sources to stimulate a cellular immune response against primary tumor cells and metastases.

Key Takeaways:

  • Antigenics has received Patent No. 5,750,119 from the PTO for its HSP-based cancer treatment technology.
  • The patent covers the use of HSP-antigen complexes derived from individual patient tumors or non-autologous tissue sources.
  • Antigenics' lead HSP product, HSPPC-96, is being tested in phase I/II clinical trials for pancreatic cancer, melanoma, and renal cell carcinoma at Memorial Sloan-Kettering and M.D. Anderson Cancer Centers.
  • Pre-clinical studies of HSPPC-96 have demonstrated successful treatment of five different types of cancer in mice, including metastatic lung cancer, melanoma, and colon carcinoma.
  • Antigenics' scientific platform is based on discoveries made by Chief Scientific Officer and Chairman of its Scientific Advisory Board, Pramod Srivastava, Ph.D.
  • The company's research programs are conducted at the University of Connecticut School of Medicine and at Antigenics' research and development facility in Lexington, MA.

Statistics:

  • Patent No. 5,750,119 has been issued to Antigenics by the U.S. Patent and Trademark Office (PTO).
  • Five different cancer types have been successfully treated in mice using HSPPC-96 (pre-clinical studies published in Science on October 3, 1997).
  • Clinical trials are being conducted at Memorial Sloan-Kettering and M.D. Anderson Cancer Centers.
  • 100% of patients in pre-clinical studies of HSPPC-96 showed successful treatment of metastatic lung cancer, melanoma, and colon carcinoma.

Sources:

  • PRNewswire release, May 12, 1998. Antigenics, L.L.C.
  • Science, October 3, 1997. Pre-clinical studies of HSPPC-96.